Biogen CEO nqis nqis tom qab tawm tsam nrog Alzheimer's Drug Aduhelm

Tojsiab

Biogen CEO Michel Vounatsos yuav tso tseg raws li lub tuam txhab txuas ntxiv txo txog $ 1 nphom hauv cov nqi txhua xyoo, Biogen tau hais rau hnub Tuesday, tom qab Medicare txwv tsis pub them rau nws cov tshuaj Alzheimer, Aduhelm, rau cov neeg mob hauv kev sim tshuaj rau lub hli tas los.

Cov Lus Tseem Ceeb

Biogen hais hauv ib xovxwm tso tawm Vounatsos yuav txuas ntxiv ua CEO thiab tseem nyob hauv lub tuam txhab pawg thawj coj mus txog thaum xaiv tus neeg ua tiav tshiab.

Vounatsos tau hais hauv nqe lus tias nws txaus siab rau Biogen "kev muaj peev xwm tsis sib xws" hauv kev tshawb fawb neuroscience, thiab nws tau tawm hauv "lub sijhawm cog lus" rau lub tuam txhab.

Lub tuam txhab kuj tau hais tias nws yuav tshem tawm cov kev muag khoom lag luam cuam tshuam nrog Aduhelm, nrog rau lwm yam kev txo nqi, uas yog npaj los muab kev txuag nyiaj txhua xyoo ntawm $ 500 lab.

Qhov no yog ntxiv rau $ 500 lab tus nqi txiav nyiaj pib Biogen tshaj tawm nyob rau lub Kaum Ob Hlis, raws li lub tuam txhab, nqa lub hom phiaj txuag nqi txhua xyoo rau $ 1 nphom.

Biogen shares tau nce 3% Tuesday sawv ntxov tom qab tshaj tawm.

Tus Keeb Kwm Tseem Ceeb

Food and Drug Administration pom zoo Aduhelm siv rau cov neeg mob uas muaj kev puas siab puas ntsws me me vim Alzheimer's kab mob nyob rau lub Rau Hli, tab sis ob lub lis piam tom qab ob pawg neeg sawv cev. qhib kev tshawb nrhiav mus rau hauv FDA txoj kev pom zoo rau cov tshuaj. Cov tsim cai lij choj thov FDA tsis quav ntsej txog kev txhawj xeeb los ntawm cov kws tshaj lij txog cov txiaj ntsig kho mob ntawm cov tshuaj, thiab tsa kev txhawj xeeb ntawm lawv tus kheej txog cov tshuaj tom qab ntawd-$ 56,000 ib xyoos ib zaug. Peb tus tswv cuab ntawm FDA's Peripheral thiab Central Nervous System Drug Advisory Committee resigned ua raws li kev pom zoo ntawm Aduhelm, thiab 18 tus kws tshawb fawb txog kev puas siab puas ntsws tau sau rau hauv a daim ntawv qhia xyoo tas los lawv tsis xav tias cov tshuaj muaj txiaj ntsig zoo. FDA tau tshaj tawm ib qho rov xyuas dua ntawm nws txoj kev pom zoo rau Aduhelm, thiab Lub Chaw rau Medicare thiab Medicaid Services txwv kev pab ntawm cov tshuaj nyob rau lub hli tas los rau cov neeg mob koom nrog hauv kev sim tshuaj - txo tus naj npawb ntawm cov neeg mob uas yuav txwv tsis pub noj.

Tus lej Loj

$28,200. Tam sim no Biogen ntau npaum li cas nqi rau ib xyoos ntawm Aduhelm, tom qab pib nqi lossis ntawm $ 56,000.

Tsis meej

Cov ntawv xov xwm Stat tsawg kawg 15 lub tsev kho mob, suav nrog Cleveland Clinic, Johns Hopkins, University of California Los Angeles thiab University of Michigan, tau txiav txim siab tsis muab Aduhelm rau cov neeg mob, hais txog qhov tsis muaj pov thawj ntawm cov tshuaj muaj txiaj ntsig.

ntxiv nyeem ntawv

Medicare Nrhiav Kev Txwv Kev Pabcuam Rau Kev Sib Tham Alzheimer's Drug Aduhelm (Forbes)

Pawg neeg hauv tsev tau nce kev tshawb nrhiav rau FDA pom zoo ntawm cov tshuaj tsis sib haum xeeb Alzheimer (Cov Washington Post)

Tau qhov twg los: https://www.forbes.com/sites/annakaplan/2022/05/03/biogen-ceo-stepping-down-after-struggles-with-alzheimers-drug-aduhelm/